Skip to content

An Enhanced Protein (Dairy) Weight Loss Intervention for Dynapenic Obesity: Impact on Muscle Quality and Composition

An Enhanced Protein (Dairy) Weight Loss Intervention for Dynapenic Obesity: Impact on Muscle Quality and Composition

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02437643
Acronym
DDYNAMO
Enrollment
81
Registered
2015-05-07
Start date
2015-08-17
Completion date
2018-10-15
Last updated
2018-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dynapenia, Obesity

Brief summary

The purpose of the trial is to assess the effects of combining regular, generous intakes of high quality protein (primarily from dairy and other animal source proteins) with calorie restriction and low-intensity exercise on muscle quality and muscle adipose infiltration (along with bone mineral density \[BMD\] and a number of secondary outcomes) in frail, obese, older adults participating in a 6 month intervention. The investigators will compare these effects to those of a traditional control regimen of calorie restriction and low-intensity exercise over the same duration.

Detailed description

Obese older adults (≥60 yrs) with moderate functional impairment will be randomized to 1 of 2 study arms. Outcomes to be measured at 0, 3 and 6 months are as follows: Primary outcomes- (1) Muscle Quality (MQ): muscle power (time to perform ten chair rises, height of the chair, leg length, body mass, and acceleration of gravity) in relation to muscle mass (CT-scan) and (2) Muscle adipose infiltration (MAI) (CT-scan). Secondary outcomes- Bone Mineral Density (BMD; DXA scan) physical function (Short Physical Performance Battery (SPPB); 6 minute walk; 8-foot up and go; and 30 second chair stands; handgrip strength; body weight; fat mass; waist circumference; activity (accelerometers); mental health (sleep, depression, quality of life); and feasibility factors (adherence, protein intake, nutrition adequacy). BMD will only be accessed at 0 and 6 months. Study Arms: * Weight loss plus low-intensity exercise intervention (WL-LoEX; n = 35): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein\ 0.8g/g/d. Subjects will also participate in three 30-minute low-intensity exercise sessions weekly. One serving of dairy protein/day will be provided to WL-LoEX participants. * High protein weight loss plus low-intensity exercise intervention (PRO-WL-LoEX; n = 35): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of \> 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from dairy foods that will be provided. Subjects will also participate in three 30-minute low-intensity exercise sessions weekly.

Interventions

BEHAVIORALWeight Loss

Participants will be prescribed hypo-caloric diet prescription.

DIETARY_SUPPLEMENTDairy Protein

Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.

Participants in both groups will participate in chair exercises 3 times a week.

Sponsors

Dairy Research Institute
CollaboratorOTHER
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* BMI \>30; * SPPB score of ≥4 to \<10; * GFR \<45 mL/min

Exclusion criteria

* Body weight \>495 lbs. (BodPod limits); * estimated glomerular filtration rates (eGFR) less than 45 mL/min; * symptomatic cardiac disease; * receiving chemotherapy; * hemophilia; * presence of unstable or symptomatic life-threatening illness; * neurological disease or disorder causing functional impairments; * inability to walk, * dementia; * prescription weight loss medications; * use of monamine oxidase inhibitors (MAOIs); or * primary medical provider advises against participation.

Design outcomes

Primary

MeasureTime frameDescription
Change in muscle qualitybaseline, 3 months, 6 monthscomposite score of time to perform ten chair rises, height of the chair, leg length, body mass, and acceleration of gravity in relation to muscle mass
Change in muscle adipose infiltrationbaseline, 3 months, 6 monthsCT-scan

Secondary

MeasureTime frameDescription
Change in Bone Mineral DensityBaseline and 6-monthsDEXA
Change in sleepbaseline, 3 months, 6 monthsPittsburgh sleep quality index
Change in depressionbaseline, 3 months, 6 monthsCenter for Epidemiologic Studies Depression Scale
Change in hand grip strengthbaseline, 3 months, 6 monthsJamar Hand Dynamometer
Change in physical activitybaseline, 3 months, 6 monthsCommunity Health Activities Model Program for Seniors (CHAMPS)
Change in quality of lifeBaseline, 3 months, 6 monthsSF-36
Change in dietary protein intakebaseline, 3 months, 6 months3-day food record
Change in Body weightbaseline, 3 months, 6 monthschange in weight
Change in lean Body Massbaseline, 3 months, 6 monthsBodPod
Change in fat massbaseline, 3 months, 6 monthsBodPod
Change in 6-minute walk timebaseline, 3 months, 6 months6-minute walk
Change in 8-foot up and go timebaseline, 3 months, 6 monthstime it takes to complete 8-foot up and go
Change in 30 second chair standsbaseline, 3 months, 6 monthsnumber of chair stands done in 30 seconds
Change in Physical Functionbaseline, 3 months, 6 monthsshort physical performance battery score
Change in calorie intakebaseline, 3 months, 6 months3-day food record

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026